BAX and breast cancer: A nonsignificant trend towards increased mammary tumour incidence was found for parous MMTV-c-myc transgenic/bax-hemizygous mice (44.4 vs 20 and 20%; P=0.39 by Wilcoxon) as compared to parous c-myc transgenic mice in which bax was intact or completely eliminated (Figure 1B).